IL232421A0 - A dual inhibitor of met and vegf for cancer treatment - Google Patents
A dual inhibitor of met and vegf for cancer treatmentInfo
- Publication number
- IL232421A0 IL232421A0 IL232421A IL23242114A IL232421A0 IL 232421 A0 IL232421 A0 IL 232421A0 IL 232421 A IL232421 A IL 232421A IL 23242114 A IL23242114 A IL 23242114A IL 232421 A0 IL232421 A0 IL 232421A0
- Authority
- IL
- Israel
- Prior art keywords
- vegf
- met
- treating cancer
- dual inhibitor
- inhibitor
- Prior art date
Links
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940125436 dual inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557358P | 2011-11-08 | 2011-11-08 | |
| PCT/US2012/064116 WO2013070890A1 (en) | 2011-11-08 | 2012-11-08 | Dual inhibitor of met and vegf for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL232421A0 true IL232421A0 (en) | 2014-06-30 |
Family
ID=47179011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232421A IL232421A0 (en) | 2011-11-08 | 2014-05-01 | A dual inhibitor of met and vegf for cancer treatment |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CN103402505A (zh) | 2010-09-27 | 2013-11-20 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| KR102030447B1 (ko) | 2011-02-10 | 2019-11-08 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| MX351133B (es) | 2011-09-22 | 2017-10-03 | Exelixis Inc | Metodo para tratar osteoporosis. |
| IN2014CN02971A (cg-RX-API-DMAC7.html) | 2011-10-20 | 2015-07-03 | Exelixis Inc | |
| JP2015515988A (ja) * | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| EP2970126B1 (en) | 2013-03-15 | 2019-03-06 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| AU2015218236B2 (en) | 2014-02-14 | 2019-06-13 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
| JP6666849B2 (ja) | 2014-03-17 | 2020-03-18 | エグゼリクシス， インコーポレイテッド | カボザンチニブ製剤の投与 |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| WO2016019285A1 (en) | 2014-07-31 | 2016-02-04 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| KR102634247B1 (ko) | 2014-08-05 | 2024-02-05 | 엑셀리시스, 인코포레이티드 | 다발성 골수종을 치료하기 위한 약물 병용물 |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| CA3020749A1 (en) * | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CA3040788C (en) * | 2016-10-18 | 2022-01-11 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
| DK3630726T3 (da) | 2017-05-26 | 2022-03-07 | Exelixis Inc | Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse |
| SG11202006921PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF |
| CN120417903A (zh) | 2023-01-31 | 2025-08-01 | 汉达癌症医药责任有限公司 | 改良的卡博替尼组合物及其使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| JP2013537918A (ja) * | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| CN103402505A (zh) * | 2010-09-27 | 2013-11-20 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
-
2012
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Ceased
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en not_active Ceased
- 2012-11-08 HK HK15102604.7A patent/HK1202062A1/xx unknown
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201818937A (zh) | 2018-06-01 |
| MX2014005458A (es) | 2015-04-16 |
| JP2014532766A (ja) | 2014-12-08 |
| TW201322981A (zh) | 2013-06-16 |
| BR112014011009A2 (pt) | 2017-06-06 |
| EA201490944A1 (ru) | 2014-10-30 |
| US20140323522A1 (en) | 2014-10-30 |
| AU2017225103A1 (en) | 2017-09-28 |
| HK1202062A1 (en) | 2015-09-18 |
| WO2013070890A1 (en) | 2013-05-16 |
| IN2014CN04067A (cg-RX-API-DMAC7.html) | 2015-10-23 |
| EP2776033A1 (en) | 2014-09-17 |
| JP2018048154A (ja) | 2018-03-29 |
| TWI662962B (zh) | 2019-06-21 |
| KR20140088610A (ko) | 2014-07-10 |
| AU2012335737A1 (en) | 2014-06-05 |
| CN104159585A (zh) | 2014-11-19 |
| CA2854336A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232421A0 (en) | A dual inhibitor of met and vegf for cancer treatment | |
| IL288181A (en) | Cancer treatment methods | |
| IL276362A (en) | Cancer treatment methods | |
| EP2760452A4 (en) | METHODS OF TREATING CANCER | |
| IL232530B (en) | A combination of factors for cancer treatment | |
| ZA201402771B (en) | Treatment of cancer with tor kinase inhibitors | |
| EP2675485A4 (en) | ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER | |
| EP2643001A4 (en) | METHOD OF TREATING CANCER | |
| IL228430A0 (en) | Cancer treatment | |
| ZA201304226B (en) | Methods of treating cancer | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| IL231234A (en) | Aromatase inhibitor for the treatment of hypogonadism and related diseases | |
| EP2709730A4 (en) | TREATMENT AND PROGNOSIS OF CANCER | |
| GB201113140D0 (en) | Prediction and treatment of cancer | |
| IL232266A0 (en) | Cancer treatment methods | |
| GB201121783D0 (en) | Treatment of cancer | |
| GB201121791D0 (en) | Combination treatment of cancer |